Analyst Ram Selvaraju of H.C. Wainwright maintained a Buy rating on Basilea Pharmaceutica, boosting the price target to CHF105.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including Basilea Pharmaceutica’s recent financial backing and strategic pipeline expansion. The company secured a significant $25 million commitment from the Biomedical Advanced Research and Development Authority (BARDA) to further the development of its novel antifungal treatments, fosmanogepix and BAL2062. This funding is part of a larger agreement that could potentially provide up to $268 million over 12 years, significantly supporting Basilea’s research and development efforts.
Additionally, Basilea’s strategic move to in-license a promising new drug candidate from Venatorx Pharmaceuticals also contributes to the Buy rating. The candidate, ceftibuten-ledaborbactam etzadroxil, is a Phase 3-ready oral antibiotic combination that shows potential in treating complicated urinary tract infections, a significant market with over 600,000 hospital admissions annually in the U.S. The drug’s established mechanism of action and promising safety profile in early studies suggest a mitigated risk path forward, which could enhance Basilea’s market position if clinical results are favorable.
Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and BridgeBio Pharma. According to TipRanks, Selvaraju has an average return of 20.3% and a 52.42% success rate on recommended stocks.
In another report released on September 20, TR | OpenAI – 4o also upgraded the stock to a Buy with a CHF53.00 price target.